Sens. Back Long-Term Protections For Biologic Drugs

Law360, New York (October 26, 2009, 8:25 PM EDT) -- In the tug-of-war over how to regulate generic versions of biologic treatments, a group of senators has joined the faction pulling for a full 12-year term of data exclusivity, saying the measure is necessary to reward pioneering companies and incentivize further innovation in the field.

In a letter Friday, a dozen senators signed a letter urging Majority Leader Sen. Harry Reid, D-Nev., to support the 12-year exclusivity period as lawmakers prepare legislation aimed at creating a regulatory pathway for brand-name biologics, also known as biosimilars....
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.